LABCORP HOLDINGS INC.

Labcorp Holdings Inc. provides comprehensive laboratory diagnostics and drug development services through two primary segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). Through its Dx segment, the company offers routine clinical testing, specialized esoteric assays, genomic analyses, and direct-to-consumer health panels. Its BLS division delivers central laboratory services, preclinical safety assessments, and analytical solutions that support clinical trials and therapeutic development. Labcorp serves a broad range of clients, including physicians, hospitals, health systems, academic researchers, and individual patients, as well as pharmaceutical, biotechnology, and medical device organizations.

The company operates an extensive service network across North America, Europe, and Asia, which includes more than 2,200 patient service centers and over 7,000 phlebotomists placed directly in customer locations. With nearly 71,000 employees based across 17 countries, Labcorp supports clinical trial activities and serves clients in approximately 100 countries globally. The provided excerpt does not disclose the location of the company's headquarters.

Summary of the business section of Labcorp's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“The Company’s nearly 71,000 employees located across 17 countries are essential to the Company’s ability to innovate and advance science and technology to empower patients, providers, and pharmaceutical companies to make clear and confident decisions.”